Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma

Future Oncol. 2016;12(8):1001-4. doi: 10.2217/fon-2015-0078. Epub 2016 Feb 12.

Authors

Gordon Alton¹, Santosh Kesari²

Affiliations

¹ Curtana Pharmaceuticals, 1624 Headway Circle, Austin, TX 78754, USA.
² John Wayne Cancer Institute, Santa Monica, CA 90404, USA.

PMID: 26867754
DOI: 10.2217/fon-2015-0078

No abstract available

Keywords: OLIG2; cancer stem cell; glioblastoma; pharmacophore; transcription factor; tumor progenitor.

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors*
Basic Helix-Loop-Helix Transcription Factors / chemistry
Basic Helix-Loop-Helix Transcription Factors / metabolism*
Drug Discovery
Glioblastoma / drug therapy
Glioblastoma / metabolism*
Humans
Molecular Targeted Therapy
Nerve Tissue Proteins / antagonists & inhibitors*
Nerve Tissue Proteins / chemistry
Nerve Tissue Proteins / metabolism*
Oligodendrocyte Transcription Factor 2

Substances

Antineoplastic Agents
Basic Helix-Loop-Helix Transcription Factors
Nerve Tissue Proteins
OLIG2 protein, human
Oligodendrocyte Transcription Factor 2